RedHill Biopharma Ltd.: RedHill gives up migraine product (RHB-103). Upside remains, but the price target is decreased to NIS 2.27. Post author:jaimeuss_admin Post published:17 בSeptember 2018 Post category:Research Continue ReadingRedHill Biopharma Ltd.: RedHill gives up migraine product (RHB-103). Upside remains, but the price target is decreased to NIS 2.27.
Oramed Pharmaceuticals (PRNewsFoto/Oramed Pharmaceuticals Inc) Oramed Pharmaceuticals Inc.: An emerging player in the huge orally delivered therapeutics segment of the global diabetes care market; we initiate our coverage with a price target of NIS 53.2 Post author:jaimeuss_admin Post published:6 בSeptember 2018 Post category:Research Continue ReadingOramed Pharmaceuticals Inc.: An emerging player in the huge orally delivered therapeutics segment of the global diabetes care market; we initiate our coverage with a price target of NIS 53.2
Cellect Biotechnology Ltd.: Significant recently reported findings open the ApoGraft™ platform to also be used in the fat-derived stem cell segment; price target raised to $16.9 Post author:jaimeuss_admin Post published:30 בAugust 2018 Post category:Research Continue ReadingCellect Biotechnology Ltd.: Significant recently reported findings open the ApoGraft™ platform to also be used in the fat-derived stem cell segment; price target raised to $16.9
Vonetize Plc: Possible acquisition of Takoomi will provide foothold in the smart video advertising space; price target unchanged Post author:jaimeuss_admin Post published:30 בAugust 2018 Post category:Research Continue ReadingVonetize Plc: Possible acquisition of Takoomi will provide foothold in the smart video advertising space; price target unchanged
Safe-T: The company continues to successfully implement its growth strategy. Raised capital, launched a new web site and marketing activities, received first orders for its newly announced solution and is gearing up for dual-trading. Price target remains at NIS 9.38. Post author:jaimeuss_admin Post published:30 בAugust 2018 Post category:Research Continue ReadingSafe-T: The company continues to successfully implement its growth strategy. Raised capital, launched a new web site and marketing activities, received first orders for its newly announced solution and is gearing up for dual-trading. Price target remains at NIS 9.38.
Brainsway Ltd.: The Company continues to generate consistent growth based on the rental model; we assume operating balance in 2018; Capital raising reflects the confidence of institutional investors. Price target remains within the forecast range. Post author:jaimeuss_admin Post published:30 בAugust 2018 Post category:Research Continue ReadingBrainsway Ltd.: The Company continues to generate consistent growth based on the rental model; we assume operating balance in 2018; Capital raising reflects the confidence of institutional investors. Price target remains within the forecast range.
BioLineRx Ltd.: Company is on track with its execution of multiple clinical development programs for the Company’s lead project – BL-8040; Sufficient funds to support this development; Stock price target raised to NIS 5.15 Post author:jaimeuss_admin Post published:30 בAugust 2018 Post category:Research Continue ReadingBioLineRx Ltd.: Company is on track with its execution of multiple clinical development programs for the Company’s lead project – BL-8040; Sufficient funds to support this development; Stock price target raised to NIS 5.15